Health Condition 1: null- urolithiasis
Conditions
Interventions
Intervention1: Cystone extract route tablet: Dose-1 tablet twice daily
Duration - 3 months
Route - oral
frequency - twice daily
Control Intervention1: Cystone tablet: Dose-2 tablet twice daily Durati
Sponsors
The Himalaya Drug
Eligibility
Inclusion criteria
Inclusion criteria: ? Subject with Urolithiasis as disgnosed by clinically as well as ultrasonographically with calculi measuring more than 5 mm. ? Hematologic and Biochemical parameters within normal limits. ? Willing to sign inform consent document
Exclusion criteria
Exclusion criteria: ? Those with serious cardiovascular, cerebrovascular, respiratory, liver or renal disease or any other disorder. ? The subjects not to have used any drugs, for at least 1 week prior to the study. ? Subjects with a strong history of food or drug allergy of any kind. ? Subjects not to have been on weight reducing diets within 3 months prior to the start of the study. ? No other drugs (including aspirin) to be ingested during the course of the study. ? Patients unwilling to provide informed consent or abide by the requirements of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptomatic relief from clinical symptoms of urolithiasis and reduction in the stone size by ultrasonographyTimepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety profile of Cystone Extract route tablet in Urolithiasis and overall compliance to the drug treatment. Timepoint: At monthly intervals for the period of 3 months | — |
Countries
India
Contacts
Public ContactDr Narasimhaswamy M S
Mandya Institute of Medical Sciences, mandya.
Outcome results
None listed